English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
-
UDIBI
Published: September 20, 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract...
-
UDIBI
An international comparative analysis and roadmap to sustainable biosimilar markets. SHOW MORE
-
UDIBI
Published: August 28, 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies More information
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. SHOW MORE
-
UDIBI
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. SHOW MORE
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). SHOW MORE
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
